button bars forest bayes pooled summary circles
 
DCR

laHNSCC - 1st line (L1) locally advanced (laHNSCC) laHNSCC - 1st line (L1)

versus placebo
avelumab alone vs. placebo 1 -

mHNSCC - L1 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - all population

versus cetuximab plus platin plus 5FU
pembrolizumab alone vs. cetuximab plus platin plus 5FU 1 -
pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU 1 -

mHNSCC - L1 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - PDL1 positive

versus cetuximab plus platin plus 5FU
pembrolizumab alone vs. cetuximab plus platin plus 5FU 2 -
pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU 2 -

mHNSCC - L2 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - all population

versus Standard of Care (SoC)
durvalumab alone vs. Standard of Care (SoC) 1 1.00 [0.63; 1.58], 1 RCT, I2=0%
inconclusive result
durvalumab plus tremelimumab vs. Standard of Care (SoC) 1 1.12 [0.72; 1.75], 1 RCT, I2=0%
inconclusive result
nivolumab alone vs. Standard of Care (SoC) 1 -
pembrolizumab alone vs. Standard of Care (SoC) 1 -

mHNSCC - L2 - PDL1 negative metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 negative

versus durvalumab alone
durvalumab plus tremelimumab vs. durvalumab alone 1 0.55 [0.25; 1.21], 1 RCT, I2=0%
inconclusive result
versus tremelimumab
durvalumab plus tremelimumab vs. tremelimumab 1 9.41 [1.22; 72.41], 1 RCT, I2=0%
unassessable degree of certainty

mHNSCC - L2 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 positive

versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 1 -

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons